Company / Return on Assets (ROA)
Intellia Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-49.0%
FY2025
5-year range
-49.0% / -20.7%
FY2021-FY2025
Trend
-12.5%
vs FY2024
Sector context
#155 of 158
Health Care
What the data says
Among 158 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for return on assets (roa). Return on Assets (ROA) has declined for 5 consecutive years, from -19.9% in FY2020 to -49.0% in FY2025.
Based on SEC 10-K filings.
-49.0% in FY2025 with a 5-year CAGR of -29.2%.
Declined from -37.0% to -49.0% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -17.8pp
- 5-Year Change
- -29.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 158This company -49.0% Sector average -2.2%
▼
-2135.3% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s return on assets (roa) has declined for 5 consecutive years.
- In FY2025, return on assets (roa) decreased 12.5% year-over-year.
- Currently 46.8pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -49.0% | -12.5% |
| FY2024 | -43.6% | -17.8% |
| FY2023 | -37.0% | -18.6% |
| FY2022 | -31.2% | -50.7% |
| FY2021 | -20.7% | -4.3% |
| FY2020 | -19.9% | +86.0% |
| FY2019 | -141.9% | -477.3% |
| FY2018 | -24.6% | -36.9% |
| FY2017 | -17.9% | -69.7% |
| FY2016 | -10.6% | +29.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026